First Danish doses delivered through COVAX arrive in Algeria

The first deliveries from a pledge of 1 million doses to be donated to COVAX by Denmark have arrived, with 57,600 doses of the AstraZeneca (AZ) vaccine to Algeria on 26 August. These will be closely followed by a delivery of 115,200 doses to Morocco. Denmark is donating doses to COVAX on top of the USD 16 million it has pledged to the Gavi COVAX Advance Market Commitment (Gavi COVAX AMC).

This donation by Denmark allows COVAX to deliver more vaccines in the third quarter of this year, before supply from COVAX purchase agreements increases in Q4, meaning that more people will be able to access vaccines now, at a time when variants are a major threat to global health and stability.

Dr Seth Berkley, CEO, Gavi, the Vaccine Alliance: “The Government of Denmark is one of the six original donors to Gavi, the Vaccine Alliance and has continued to support equitable access to vaccines over the last 20 years. In addition to its already generous funding of COVAX, Denmark’s dose donations will help protect health care workers and those most-at-risk wherever they are and whatever their income level.”

Flemming Møller Mortensen, Minister for Development Cooperation and Minister for Nordic Cooperation of Denmark: “I’m pleased that this batch of vaccines are going to help Algerians. Nobody is safe until everybody is safe. That’s why Denmark has donated 1 million vaccines and 16 million USD to COVAX – and we are committed to continue to do our part in this battle against the Pandemic.”

These doses donated by Denmark are produced by the AstraZeneca manufacturing network. Donating through COVAX helps to increase vaccine coverage, ensures that no dose goes to waste, and helps to bring an end to the acute phase of the pandemic. The design and operationalization of the COVAX dose sharing mechanism is being supported by a contribution of CAD 5 million from Canada.

The donation of doses via COVAX are enabled via tripartite agreements between Gavi, manufacturers, and donating countries. The shipments to countries will be enabled by COVAX delivery partners UNICEF and the Pan American Health Organisation (PAHO).

Over 600 million doses have already been pledged to COVAX by a number of countries in response to short-term supply challenges and the rise of new variants. Working with donor governments to operationalise growing numbers of dose-sharing pledges, COVAX expects to see more deliveries of donated doses in the weeks and months to come.

About COVAX

COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, is co-led by CEPI, Gavi and WHO – working in partnership with developed and developing country vaccine manufacturers, UNICEF, PAHO, the World Bank, and others. It is the only global initiative that is working with governments and manufacturers to ensure COVID-19 vaccines are available worldwide to both high-income and lower-income countries.

Gavi’s role in COVAX

Gavi leads on procurement and delivery at scale for COVAX: designing and managing the COVAX Facility and the Gavi COVAX AMC and working with its traditional Alliance partners UNICEF and WHO, along with governments, on country readiness and delivery. As part of this role, Gavi hosts the Office of the COVAX Facility to coordinate the operation and governance of the mechanism as a whole, holds financial and legal relationships with 193 Facility participants, and manages the COVAX Facility deals portfolio: negotiating advance purchase agreements with manufacturers of promising vaccine candidates to secure doses on behalf of all COVAX Facility participants. Gavi also coordinates design, operationalisation and fundraising for the Gavi COVAX AMC, the mechanism that provides access to donor-funded doses of vaccine to 92 lower-income economies. As part of this work, Gavi provides funding and oversight for UNICEF procurement and delivery of vaccines to all AMC participants – operationalising the advance purchase agreements between Gavi and manufacturers – as well as support for partners’ and governments work on readiness and delivery. This includes tailored support to governments, UNICEF, WHO and other partners for cold chain equipment, technical assistance, syringes, vehicles, and other aspects of the vastly complex logistical operation for delivery. Gavi also co-designed, raises funds for and supports the operationalisation of the AMC’s no-fault compensation mechanism as well as the COVAX Humanitarian Buffer.

About Gavi, the Vaccine Alliance

Gavi, the Vaccine Alliance is a public-private partnership that helps vaccinate half the world’s children against some of the world’s deadliest diseases. Since its inception in 2000, Gavi has helped to immunise a whole generation – over 822 million children – and prevented more than 14 million deaths, helping to halve child mortality in 73 lower-income countries. Gavi also plays a key role in improving global health security by supporting health systems as well as funding global stockpiles for Ebola, cholera, meningitis and yellow fever vaccines. After two decades of progress, Gavi is now focused on protecting the next generation and reaching the unvaccinated children still being left behind, employing innovative finance and the latest technology – from drones to biometrics – to save millions more lives, prevent outbreaks before they can spread and help countries on the road to self-sufficiency.